

Recognizing & Treating the Many Faces of ATTR Amyloidosis

An update from a neurologist's perspective

This Satellite Symposium is Supported by Pfizer Inc.

Sunday, 24 May 2020 | 18:30 - 20:00

Virtual Event

Objectives:

- Highlight the physiological role of transthyretin (TTR)
- Review the pathology and systemic nature of hATTR amyloidosis, emphasizing the multidisciplinary aspects
- Underscore the importance of early identification and the correct application of diagnostic tools
- Review the latest efficacy and safety data of currently approved treatments for hATTR amyloidosis
- Discuss the importance of a multidisciplinary approach to hATTR management and treatment

Our Faculty

Jean-Philippe Camdessanché, MD
Saint-Étienne, France

Lucía Galán, MD, PhD
Madrid, Spain

Laura Obici, MD
Pavia, Italy

Time	Topic
18:30 - 18:35	Welcome and Overview Jean-Philippe Camdessanché, MD
18:35 - 18:55	What is Amyloidosis? Laura Obici, MD
18:55 - 19:15	How to Achieve Early Patient Identification and Diagnosis? Jean-Philippe Camdessanché, MD
19:15 - 19:45	What Are the Therapeutic Options for Patients? Lucía Galán, MD, PhD
19:45 - 20:00	Q&A Moderator: Jean-Philippe Camdessanché, MD